Background Back in 2004, following corresponding legislation in the US (Hatch Waxman Act) Israel amended their Patent Law to Provide for patent term extensions with what is known as the third amendment the Israel Patent Law. This creates a… Read More ›
Patent Term Extension
In Israel, Patent Term Extensions are available for basic patents to ensure at least 9 years of monopolistic sales from the first regulatory approval for a drug covered by the patent. The extension may be for anything up to five years. So… Read More ›
Bristol-Myers Squibb and Pfizer have requested a Patent Term Extension for IL 160693 titled “Lactam-Containing Compound or Pharmaceutically Acceptable Salt Thereof as Factor Xa Inhibitor and Pharmaceutical Compositions Containing It” for Apixaban which is the active ingredient of Eliquis which was… Read More ›
Neurim’s appeal against the refusal of the UK Patent Office to issue a Supplementary Protection Certificate for Circadin has been referred to the European Court of Justice –the CJEU by the Court of Appeal.
What is the first use of a pharamceutical product?